Macquarie Group LTD Kura Oncology, Inc. Transaction History

Macquarie Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$11.23 - $16.9 $5,805 - $8,737	-517 Reduced 52.43%	469 $5,000
Q3 2022 Nov 14, 2022	SELL	$12.01 - $19.45 $5,740 - $9,297	-478 Reduced 32.65%	986 $26,000
Q1 2021 May 14, 2021	SELL	$24.75 - $39.14 $11,112 - $17,573	-449 Reduced 23.47%	1,464 $41,000
Q2 2020 Aug 11, 2020	BUY	$7.95 - $18.81 $15,208 - $35,983	1,913 New	1,913 $31,000
Q1 2019 May 15, 2019	SELL	$13.73 - $16.87 $4,119 - $5,061	-300 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$16.65 - $21.85 $4,995 - $6,555	300 New	300 $5,000
Q1 2018 May 11, 2018	SELL	$14.5 - $23.4 $8,700 - $14,040	-600 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$13.5 - $16.65 $8,100 - $9,990	600	600 $9,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.